40 results found

In its decision of 14 December 2015, the Swiss Federal Supreme Court had confirmed that the practice of the Federal Office of Public Health (FOPH) which, in the course of the regular triennial review, determines the prices of drugs...

The National Council and the Council of States have adopted the revised Therapeutic Products Act during the federal parliament's spring session of 2016.

On 21 September 2019, the Federal Council decided to implement several parts of the amendments adopted in the spring session 2016 regarding the legislation ...

On 1 September 2017, the revised law on reproductive medicine and the revised reproductive medicine ordinance came into force in Switzerland

In 2025, federal scrutiny of Pharmacy Benefit Managers (PBMs) has reached a level not seen before. What was once tolerated as opaque and self-serving practices is now the subject of a coordinated...

Switzerland is moving ahead with the implementation of the Cost Containment Package 2: On 18 February 2026, the Federal Council opened the consultation on a third set of significant revisions...

Bär & Karrer, a Swiss law firm, provides comprehensive legal and business solutions. Contact their Zurich office for expert assistance with legal advice, business inquiries, and professional services tailored to your needs.

In einem Grundsatzentscheid vom 30. April 2015 hat das Bundesverwaltungsgericht entschieden, die bald fünfjährige Praxis des Bundesamts für Gesundheit (BAG)...

According to the current regulatory set-up in Switzerland, it is permissible to sell and purchase cannabis products, as long as the THC level remains below 1%.

The European Patent Office (EPO) has launched a series of initiatives to measure and encourage innovation in digital agriculture across the EU.

Das Bundesgericht hatte mit Urteil vom 14. Dezember 2015 bestätigt, dass die Praxis des Bundesamts für Gesundheit (BAG), die Preise von Arzneimitteln der Spezialitätenliste (SL) bei der ordentlichen Dreijahresüberprüfung grundsätzlich nur im Vergleich mit den Auslandpreisen zu überprüfen, gegen das Krankenversicherungsgesetz (KVG) verstösst.

Am 3. September 2025 hat der Bundesrat die Botschaft zur Teilrevision des HMG zuhanden des Parlaments verabschiedet.

Die heutige Dopingpolitik mit ihrer angeblichen Sorge um die Gesundheitsgefährdung von Spitzensportlern ist von Widersprüchen geprägt und möglicherweise verfassungswidrig.

Swiss healthcare regulation is spread over various statutes, ordinances and guidelines, including self-regulatory instruments such as best practice codes and references to international provisions.

According to Swiss nomenclature, the term therapeutic products covers medicinal products as well as medical devices.

Switzerland's medical device regulatory framework in 2026 presents a complex landscape shaped by alignment with EU standards, post-Brexit market access challenges, and evolving requirements for product registration and transparency. How do manufacturers navigate classification systems, conformity assessments, and post-market surveillance obligations while managing the implications of Switzerland's third-country status for medical devices in the European Union?

Medicinal products are products of chemical or biological origin which are intended or claimed to have a medicinal effect on the human organism, in particular in the diagnosis, prevention or treatment of diseases...

Swiss healthcare regulation is spread over various statutes, ordinances and guidelines, including self-regulatory instruments such as best practice codes and references to international provisions.